February 22, 2018
-- Kite to Receive Exclusive License to Leverage Sangamo’s Gene Editing Technology in Allogeneic and Autologous Cell Therapy Programs in Oncology --
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180222005488/en/
Kite will use Sangamo’s ZFN technology to modify genes to develop next-generation cell therapies for autologous and allogeneic use in treating different cancers. Allogeneic cell therapies from healthy donor cells or from renewable stem cells would provide a potential treatment option that can be accessed directly within the oncology infusion center, thus reducing the time to infusion for patients.
Under the terms of the agreement, Sangamo will receive an upfront
payment of
“This collaboration between Kite and Sangamo brings together two leading
platforms to develop best-in-class cell therapies in oncology,” said
“The emergence of gene editing as a tool to edit immune cells holds
promise in the development of therapies with potentially improved
safety, efficacy and efficiency,” said
This transaction is subject to clearance under the Hart-Scott Rodino Antitrust Improvements Act and other customary closing conditions. A Current Report on Form 8-K describing the proposed transaction in more detail will be filed by Sangamo, and this press release is subject to further detail provided in Sangamo’s 8-K.
Sangamo Conference Call
Sangamo will host a conference call today,
The conference call dial-in numbers are (877) 377-7553 for domestic
callers and (678) 894-3968 for international callers. The conference ID
number for the call is 4392918. Participants may access the live webcast
via a link on the
About Kite
Kite, a
About
Gilead Sciences is a biopharmaceutical company that discovers, develops
and commercializes innovative therapeutics in areas of unmet medical
need. The company’s mission is to advance the care of patients suffering
from life-threatening diseases. Gilead has operations in more than 35
countries worldwide, with headquarters in Foster City,
About
Gilead Forward-Looking Statements
This press release includes forward-looking statements, within the
meaning of the Private Securities Litigation Reform Act of 1995 that are
subject to risks, uncertainties and other factors, including the
possibility that clearance under the Hart-Scott Rodino Antitrust
Improvements Act may not be obtained, the closing conditions may not be
met and the agreement may not become effective. In addition, Kite may be
unsuccessful in developing and commercializing cell therapies utilizing
the ZFN technology, the development of such products may take longer
than expected and the benefits of the partnership may not be realized.
All statements other than statements of historical fact are statements
that could be deemed forward-looking statements. Investors are cautioned
that any such forward-looking statements are not guarantees of future
performance and involve risks and uncertainties and are cautioned not to
place undue reliance on these forward-looking statements. Actual results
may differ materially from those currently anticipated due to a number
of risks and uncertainties. Risks and uncertainties that could cause the
actual results to differ from expectations contemplated by
forward-looking statements include risks and uncertainties detailed from
time to time in
Sangamo Forward-Looking Statements
This press release contains or may imply "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. These
forward-looking statements include, without limitation references
relating to the potential benefit of therapeutic applications of
Sangamo's ZFN technology platform to modify genes to develop
next-generation cell therapies for autologous and allogeneic use in
treating different cancers, the potential of Sangamo's ZFN technology to
provide a treatment option that can be accessed directly within the
hospital, thus reducing the time to infusion for patients, statements
related the anticipated effectiveness of the collaboration and the
timing and benefits thereof, Sangamo’s receipt of an upfront payment and
potential receipt of development- and sales-based milestones, as well as
royalties on potential future sales, and other statements that are not
historical fact Because such statements deal with future events and are
based on current expectations, they are subject to various risks and
uncertainties and actual results, performance or achievements could
differ materially from those described in or implied by the statements
in this press release due to a number of factors, including the ability
to cause the agreement to become effective on the proposed terms and
schedule, the ability to obtain clearance under the Hart-Scott-Rodino
Antitrust Improvements Act and to satisfy the closing conditions, the
new, uncertain and time consuming gene editing product candidate
development and regulatory process, including the risks that Sangamo and
Kite may not be successful in their research efforts under the
collaboration and that, even if successful, Kite may be unable to
successfully develop and commercialize licensed products resulting from
the collaboration; Sangamo’s dependence on collaborative partners,
including the risks that if Kite were to breach or terminate the
agreement or otherwise fail to successfully develop and commercialize
licensed products resulting from the collaboration and in a timely
manner, Sangamo would not obtain the anticipated financial and other
benefits of the collaboration and the development and/or
commercialization of Sangamo’s gene editing technology could be delayed,
perhaps substantially. These forward-looking statements are subject to
risks and uncertainties, including those discussed under the heading
"Risk Factors" in Sangamo’s most recently filed Quarterly Report on Form
10-Q, including the documents incorporated by reference therein, and
subsequent filings with the SEC, including Sangamo’s Annual Report on
Form 10-K for the year ended
View source version on businesswire.com: http://www.businesswire.com/news/home/20180222005488/en/
Source:
Gilead/Kite
Investors
Sung Lee, 650-524-7792
or
Media
Nathan
Kaiser, 650-522-1853
Sangamo
Investors
McDavid
Stilwell or Varant Shirvanian, 510-970-6005
or
Media
Ryan
Ferrell and John Kang, 312-506-5202
[email protected]